Gene Therapy Market & Pipeline Assessed by DelveInsight in New Market Research Report Published at MarketPublishers.com24 Feb 2015 • by Natalie Aster
LONDON – Gene therapy shows promise to become one of the most significant frontiers in the medical world. Though no considerable achievements for curing illnesses have been made, future appears to hold great potential concerning the development of such approaches. Advances in gene therapy have useful data, which has facilitated an understanding of the pathogenesis of diseases. The discipline holds forth a hope for the biotechnology industry in the long run, as the approach is shifting from research laboratories to clinical trials. The gene therapy sector remains at the experimental stages with success yet to be attained in fully developing curative therapeutic options.
Currently, more than 290 indications are being addressed by gene therapy clinical trials, out of which oncology is the most explored indication so far. Giving consideration to the use of vectors in gene therapy, there are close to 59% for viral vectors, 24% for RNA interference (RNAi) therapeutics and 17% for non-viral vectors.
New market research study “Gene Therapy Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape” created by DelveInsight presents an all-encompassing analysis of the global gene therapy market landscape.
It covers over 300 gene therapies for 15 different therapy fields including central nervous system, oncology, ophthalmology, genetic conditions, immunology and other therapy areas. The study gives an overview of over 125 small to large scale pharma companies engaged in various therapeutic fields of gene therapy utilising over 90 novel technology platforms for getting the first mover advantage. The report gives detailed insights into the number of gene therapies by vectors used, the number of gene therapies in clinical studies. It provides prediction analysis of early market winners of the pre-clinical and clinical therapies, discusses pre-clinical and clinical outcomes of gene therapies, sheds light on discontinued and dormant pipeline projects, and uncovers key trends in gene therapy partnering deals. An in-depth analysis of key market trends and driving factors, as well as manacles of gene therapy is included.
Gene Therapy Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape
Published: January, 2015
Price: US$ 6,000.00
More new research reports by the publisher can be found at DelveInsight page.